Table 2 Summary of Reported Cases of EBVMCU disease
Age | Sex | Ulcer location | Predisposing factor | Treatment | Response (durability) | Ref |
|---|---|---|---|---|---|---|
Iatrogenic immunosuppression-associated EBVMCU | ||||||
53 | F | Colon, rectum | Methotrexate + infliximab (CD) | Reduced IS | PD→HL | [75] |
56 | F | Skin (leg) | Methotrexate (PM) | Reduced IS | CR (33Â m) | [76] |
59 | F | Eyelid | Methotrexate (RA) | Reduced IS | CR (37 mo) | [76] |
60 | F | Lip mucosa | Methotrexate (RA) | Reduced IS | CR (72 mo) | [20]b |
61 | F | Skin (leg) | Methotrexate (RA) | R-CHOP | CR (25 mo) | [76] |
62 | F | Lip, nose, eyelid | Methotrexate (PM) | Reduced IS | CR (1 mo) | [45] |
64 | F | Buccal mucosa | Methotrexate (RA) | Reduced IS | Dieda | [76] |
65 | M | Palate | Methotrexate (RA) | Reduced IS | CR (19 mo) | [77] |
69 | F | Colon | Methotrexate (RA) | NR | NR | [20]b |
76 | F | Eyelid | Methotrexate (RA) | Reduced IS | CR (24 mo) | [76] |
80 | M | Tongue base | Methotrexate (RA) | NR | NR | [20]b |
80 | F | Skin (arm) | Methotrexate (RA) | Reduced IS | CR (60 mo) | [20]b |
81 | F | Tongue | Methotrexate (RA) | Reduced IS | CR (12 mo) | [78] |
42 | M | Oral mucosa | Azathioprine (sarcoidosis + MG) | NR | NR | [20]b |
63 | M | Skin (perianal) | Azathioprine (CD) | Reduced IS | CR (6Â weeks) | [79] |
75 | F | Esophagus | Azathioprine (RA) | Reduced IS | CR (17 mo) | [20]b |
76 | F | Buccal mucosa | Azathioprine (Pemphigoid) | Reduced IS | CR (13 mo) | [80] |
81 | F | Colon | Azathioprine (ITP) | None | PD on diagnosis | [81] |
48 | F | Tongue | Cyclosporine-A (SLE) | Reduced IS | CR (24 mo) | [20]b |
64 | F | Colon | Cyclosporine-A (HSCT) | Reduced IS | CR (6 mo) | [20]b |
70 | M | Lip | Cyclosporine-A, prednisone (renal transplant) | Reduced IS, surgical excision | CR (111 mo) | [82] |
80 | F | Rectum | Cyclosporine-A (UC) | Reduced IS | CR (23 mo) | [20]b |
63 | F | Gingiva | Cyclosporine-A, prednisone, MMF (renal transplant) | Reduced IS | CR (8 mo) | [82] |
44 | M | Tongue | MMF, pred (renal transplant) | Reduced IS | CR (15 mo) | [82] |
45 | M | Gingiva | MMF (SLE) | NR | NR | [83] |
61 | M | Esophagus | MMF, pred (renal transplant) | Reduced IS | CR (16 mo) | [82] |
70 | M | Rectum | MMF, pred (renal transplant) | Reduced IS, rituximab (2 doses) velcade | CR (17 mo) | [82] |
18 | M | Tonsil, buccal mucosa | MMF, prednisone, tacrolimus (cardiac transplant) | Reduced IS, rituximab (2 doses) | CR (14 mo) | [82] |
32 | M | Terminal ileum | MMF, prednisone, tacrolimus (bilateral lung transplant) | Reduced IS, rituximab (4 doses) | CR (60 mo) | [82] |
Primary Immunodeficiency-Associated EBVMCU | ||||||
45 | F | Gingiva | T-cell deficiency NOS | rituximab (8 doses) | CR (24 mo) | [62] |
61 | F | Esophagus (multifocal) | hypogammaglobulinemia | rituximab (4 doses), IVIG (monthly), brentuximab (3 cycles) | PD | [63] |
EBVMCU of Unclear Etiology | ||||||
49 | F | Gingiva, palate | etiology not established | rituximab (4 doses × 2) RT | PD CR (6 mo) | This case |
EBVMCU secondary to age-associated immunosenescence | ||||||
63 | F | Tonsil | Age | NR | NR | [20] |
64 | F | Tongue, oral mucosa | Age | RT | CR (15 mo) | [20]b |
68 | F | Tongue | Age | None | SR (36 mo) | [20]b |
68 | F | Tonsil | Age | R-CHOP, RT | CR (24 mo) | [20]b |
73 | M | Tonsil, tongue | Age | None | RR (12 mo) | [20]b |
74 | M | Skin (neck) | Age | R-CHOP | CR (24 mo) | [84] |
75 | F | Skin (arm) | Age | NR | NR | [20]b |
76 | M | Tongue base | Age | None | SR (12 mo) | [20]b |
79 | M | Skin (cheek) | Age | None | SR (25 mo) | [20]b |
80 | F | Palate | Age | RT | CR (60 mo) | [20]b |
81 | F | Palate | Age | None | SR (14 mo) | [85] |
82 | F | Lip | Age | None | RR (NR) | [20]b |
82 | M | Lip | Age | None | SR (NR) | [20]b |
84 | F | Tongue, floor of mouth | Age | None | SD (5 mo) | [20]b |
85 | F | Tonsil | Age | RT | CR (3 mo) | [20]b |
88 | F | Tongue base | Age | None | RR (24 mo) | [20]b |
88 | M | Skin (chest) | Age | None | SR (3 mo) | [20]b |
89 | M | Tongue base | Age | NR | NR | [20]b |
89 | M | Lip, skin (scalp) | Age | resection | NR | [86] |
101 | M | Tonsil | Age | R-CHOP | CR (12 mo) | [20]b |